COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

NCT07245680 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

186

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension (PAH)
Comorbidities
Cardiovascular Disease (CVD)

Interventions

DRUG: Tadalafil
DRUG: Ambrisentan
DRUG: Placebo (Ambrisentan-matching)

Sponsor

Assistance Publique - Hôpitaux de Paris